Phaseline

Companies › Suzhou Sanegene Bio

Suzhou Sanegene Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGB-9768
Factor B (CFB) inhibitor
CFBPhase 2IgA Nephropathy (IgAN)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06786338SGB-9768Phase 2IgA Nephropathy (IgAN)GenitourinaryDec 2026

Targets

CFB (1)

Companies with the same targets

Regeneron Pharmaceuticals Kriya Therapeutics Novartis Nanjing Chia-tai Tianqing Pharmaceutical

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma R1 Therapeutics Prokrea BCN

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.